drugset / Trial / NCT02949895

Study of BMS-986012 in Subjects With Small Cell Lung Caner

NCT02949895

Phase 1 Completed 7 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A study to evaluate safety and tolerability of BMS-986012 in patients with small cell lung cancer

Timeline

Start
2016-11-29
Primary completion
2017-08-29
Completion
2017-08-29

Drugs

EvaluationDrugModalityDoseRoute
Subject atigotatug Monoclonal antibody
Background Cisplatin Other / unclassified
Background Etoposide Small molecule